Genmab — Oktober 2017
-
Why would Celgene want to spend billions on a collaboration with Bluebird? Why would Novartis do the same with Juno? And why would Gilead buy Kite for 11.9 billion USD? One of them might be stupid, but not all 3!
-
Enig royal. Det er den negative side. Men på den positive side, skal så nævnes, at det er en behandling, og så er du kureret!
-
royal det er det i dag, men teknologien er jo helt ny og vi har kun set toppen af hvad den kan performe - der arbejdes jo hårdt på at gøre det billigere og uden de fatale bivirkninger. Det sker selvfølgelig ikke i morgen med i takt med at flere CAR-T terapier godkendes kommer de rnaturligvis flere og flere steder den tilbydes
-
men det er vel det man i øjeblikket mener?
-
The two greatest benefits of this therapy are that the chimeric receptors ensure that this therapy is a targeted therapy, and most importantly –since CAR T-cells are “live cells”– they are expected to amplify in the patient to establish immune memory, provide continuous surveillance
-
Det er vist en uge på lykkepiller, der venter forude
God dag til alle -
Apropos konkurrenter så se denne her https://news.northwestern.edu/stories/2017/october/suicide-molecules-kill-any-cancer-cell/ Spændende
-
Måske Genmab skulle forsøge at få fat i det Mcjean. De har jo masser af penge.
-
Der har lige været myeloma-møde i Edinburgh. Her er et par meninger om Car-T og bispecifikke antistoffer: https://www.youtube.com/watch?v=9IaUy7A3WgQ
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind